Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) announced that the multi-center, randomized, double-blind, placebo-controlled phase III clinical trial (REBUILDING-2) of the safety and efficacy of RAY1225 injection, an innovative polypeptide drug independently developed by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as “Zhongsheng Ruichuang”), the holding subsidiary of the company, recently obtained top-line analysis data. Preliminary results showed that RAY1225 injection showed positive efficacy and good safety in Chinese adult obesity/overweight participants. The test results were ideal and achieved the intended goals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.